Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Chief Medical Officer | January 04, 2024 | January 08, 2024 |
| LeonaBio, Inc.LONA · Entity 1487 | CHIEF MEDICAL OFFICER | April 09, 2026 | April 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,800 |
Reported balance
After 2024-01-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-04 · Grant · Acquired 75,000 · Balance 206,800 F1: Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments. |
| Common StockSEC Table I · non-derivative | Direct | 206,000 |
Reported balance
After 2024-01-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-01-05 · Sale · Disposed 800 · Balance 206,000 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.54 to $34.49, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 202,900 |
Reported balance
After 2024-01-05 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-01-05 · Sale · Disposed 3,100 · Balance 202,900 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 198,497 |
Reported balance
After 2024-01-05 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2024-01-05 · Sale · Disposed 4,403 · Balance 198,497 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments.
F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3: Partial disposition of RSUs to satisfy tax withholding obligations.
F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.54 to $34.49, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
LeonaBio, Inc.
Report date April 09, 2026 · Filed April 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.54 · Expires 2036-04-08 | Direct | 350,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 350,000 · Balance 350,000 F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2026 Filed Apr 13, 2026 20:51 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001794629-26-000006 · form4-04132026_080459.xml · derivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:59 UTC | LeonaBio, Inc. LONA · Entity 1487 | SaleCommon Stock | 1,720 | $5.37 | $9,236.40 |
DisclosureSEC source: 0001794629-26-000004 · form4-03052026_110324.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,887 F1 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:59 UTC | LeonaBio, Inc. LONA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 7,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001794629-26-000004 · form4-03052026_110324.xml · derivative · entry 3 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,418 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F4 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 7,418 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: On March 3, 2025, the reporting person was granted 7,418 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:59 UTC | LeonaBio, Inc. LONA · Entity 1487 | Exercise / conversionCommon Stock | 7,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001794629-26-000004 · form4-03052026_110324.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 00:52 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 1,644 | $6.88 | $11,310.72 |
DisclosureSEC source: 0001794629-26-000002 · form4-01062026_120132.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,189 F2 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 00:52 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 4,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001794629-26-000002 · form4-01062026_120132.xml · derivative · entry 3 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: RSUs convert into common stock on a one-for-one basis. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F6 · derivative.exercise_date: On October 1, 2024, the reporting person was granted 14,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F6 · derivative.expiration_date: On October 1, 2024, the reporting person was granted 14,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 00:52 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 4,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001794629-26-000002 · form4-01062026_120132.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split"). Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 21:14 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 44,508 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001794629-25-000003 · form4-12292025_091206.xml · derivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,508 Underlying: Common Stock · 44,508 shares Expires 2035-09-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: On September 24, 2025, the reporting person was granted an option to purchase 44,508 shares of common stock. The option was scheduled to vest only upon satisfaction of both a milestone requirement (the "Milestone Requirement") and a service-based requirement (the "Service-Based Requirement"). The Milestone Requirement was satisfied on December 23, 2025. The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026 and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:33 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 10,842 | $0.29 | $3,182.13 |
DisclosureSEC source: 0001415889-25-019068 · form4-07022025_080743.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,665 F1 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:33 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 46,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019068 · form4-07022025_080743.xml · derivative · entry 3 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: RSUs convert into common stock on a one-for-one basis. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F5 · derivative.exercise_date: On October 1, 2024, the reporting person was granted 140,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F5 · derivative.expiration_date: On October 1, 2024, the reporting person was granted 140,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:33 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 46,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019068 · form4-07022025_080743.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:29 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantRestricted Stock Units · Derivative | 74,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006534 · form4-03042025_090304.xml · derivative · entry 2 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,180 Underlying: Common Stock · 74,180 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3 · derivative.exercise_date: 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date. F3 · derivative.expiration_date: 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:29 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 111,270 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001415889-25-006534 · form4-03042025_090304.xml · derivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,270 Underlying: Common Stock · 111,270 shares Expires 2035-03-02 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:05 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 10,826 | $0.56 | $6,083.13 |
DisclosureSEC source: 0001415889-25-000544 · form4-01032025_100122.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,841 F1 · kind: Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5414 to $0.5939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:05 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionRestricted Stock Units · Derivative | 46,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000544 · form4-01032025_100122.xml · derivative · entry 3 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,333 Underlying: Common Stock · 46,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: RSUs convert into common stock on a one-for-one basis. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F5 · derivative.exercise_date: On October 1, 2024, the reporting person was granted 140,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F5 · derivative.expiration_date: On October 1, 2024, the reporting person was granted 140,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:05 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 46,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000544 · form4-01032025_100122.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 23:13 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001415889-24-024685 · form4-10032024_111055.xml · derivative · entry 2 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2034-09-30 F3 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 23:13 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantRestricted Stock Units · Derivative | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024685 · form4-10032024_111055.xml · derivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F2 · derivative.exercise_date: One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. F2 · derivative.expiration_date: One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 20:37 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010877 · form4-04162024_080456.xml · derivative · entry 1 San Martin Javier · CIK 0001794629 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-04-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option will vest on the one (1) year anniversary of the date of grant, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2024 Inducement Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,403 | $35.64 | $156,922.92 |
DisclosureSEC source: 0001628280-24-000865 · wk-form4_1704752165.xml · nonDerivative · entry 4 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,497 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $35.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,100 | $35.03 | $108,593.00 |
DisclosureSEC source: 0001628280-24-000865 · wk-form4_1704752165.xml · nonDerivative · entry 3 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,900 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 800 | $34.11 | $27,288.00 |
DisclosureSEC source: 0001628280-24-000865 · wk-form4_1704752165.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,000 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.54 to $34.49, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 22:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-000865 · wk-form4_1704752165.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,800 F1 · shares: Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 19:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,942 | $29.00 | $143,318.00 |
DisclosureSEC source: 0001628280-23-039850 · wk-form4_1700681491.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,800 F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.15, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 19:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 14,758 | $28.73 | $423,997.34 |
DisclosureSEC source: 0001628280-23-039850 · wk-form4_1700681491.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,742 F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.90, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002119 · doc4.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,500 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:05 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCOMMON STOCK | 200 | $30.62 | $6,124.00 |
DisclosureSEC source: 0001209191-22-058469 · doc4.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,500 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.61 to $30.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:05 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCOMMON STOCK | 19,300 | $29.98 | $578,614.00 |
DisclosureSEC source: 0001209191-22-058469 · doc4.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,700 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $30.55, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 21:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100 | $70.99 | $7,099.00 |
DisclosureSEC source: 0001209191-21-066123 · doc4.xml · nonDerivative · entry 3 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,000 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 21:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,696 | $70.01 | $398,776.96 |
DisclosureSEC source: 0001209191-21-066123 · doc4.xml · nonDerivative · entry 2 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,100 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.54 to $70.36, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 21:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 13,704 | $69.01 | $945,713.04 |
DisclosureSEC source: 0001209191-21-066123 · doc4.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,796 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.54 to $69.53, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 23:03 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 19,500 | $69.39 | $1,353,105.00 |
DisclosureSEC source: 0001209191-20-059753 · doc4.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,500 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.